Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin

US FDA Clears Monotherapy Use

 
• By Joseph Haas
  
Research scientist
Seagen's ADC Tivdak, partnered with Genmab, obtains US approval, positions for other indications

More from Clinical Trials

More from R&D